Category: triple agonist of GLP-1, GIP and glucagon receptors; currently in clinical trials (antidiabetic and strong anti-obesity drug)

Active substance: retatrutide

Packaging: vial / 10 mg

Half-life: approx. 6–8 days, allows once-weekly administration

Abused dosage: titration from 1 mg once weekly up to 10  mg once weekly

Duration of use: long-term treatment